HealthyPhase 1NCT03143725
Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution
A Phase 1 study testing GLPG1972 in people with Healthy, run by Lakefront Biotherapeutics NV at 1 site in Belgium.
Trial summary
This study is a Phase I, randomized, open-label, cross-over study with 4 single-dose treatments of GLPG1972 to compare the bioavailability of the oral wet granulation (WG) tablet relative to an oral solution and to the oral direct compression (DC) tablet after single dose intake in healthy male subjects and to… Read more about this study
- Who is it for?
- Ages 18 to 50 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- GLPG1972
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteBelgium
- Study dates
- 14 Apr 2017to 6 Jun 2017
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male between 18 and 50 years of age, inclusive,
- A body mass index (BMI) between 18-30 kg/m², inclusive, weight of at least 50 kg.
- Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and laboratory findings.
- Discontinuation of all medications except occasional paracetamol at least 2 weeks or 5 half-lives prior to the first study drug administration.
- Non-smokers and not using any nicotine-containing products.
- Negative urine drug screen and alcohol breath test.
Show all 9Show fewer
- Current sexually active male agrees to use adequate contraception
- Willing to consume a non-vegetarian high-fat and high-calorie breakfast
- Able and willing to sign the ICF
Who cannot join
- Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug
- Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or any history of hepatitis from any cause with the exception of hepatitis A.
- History of or a current immunosuppressive condition
- Symptoms of clinically significant illness in the 3 months before the initial study drug administration.
- History of malignancy within the past 5 years
- Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g. QTcF >450 msec, or a known long QT syndrome).
Show all 18Show fewer
- Presence of abnormal liver function
- Renal function with an estimated creatinine clearance <80 ml/min based on the Cockcroft-Gault formula.
- Presence of any condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
- Clinically relevant abnormalities detected on "vital signs"
- Dietary requirements precluding participation.
- Significant blood loss including blood donation or had a transfusion of any blood product within 12 weeks
- Hemoglobin level <7.5 mmol/L (12 g/dL).
- Active drug or alcohol abuse within 2 years prior to the initial study drug administration.
- Current (2 weeks before screening) and planned uninterrupted consumption of large quantities (> 6 cups) of coffee
- Administration of an injectable drug within 30 days prior to the initial study drug administration.
- Concurrent participation, or participation in a drug/device study within 8 weeks or 5 half-lives of the drug or within 6 months for biologicals
- Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Open-label Study to Compare the Bioavailability of an Oral Wet Granulation Tablet of GLPG1972 Relative to an Oral Solution and to an Oral Direct Compression Tablet After Single-dose Intake in Healthy Subjects, and to Evaluate the Effect of Food on the Bioavailability of an Oral Wet Granulation Tablet.
This study is a Phase I, randomized, open-label, cross-over study with 4 single-dose treatments of GLPG1972 to compare the bioavailability of the oral wet granulation (WG) tablet relative to an oral solution and to the oral direct compression (DC) tablet after single dose intake in healthy male subjects and to evaluate the effect of food on the bioavailability of the WG oral tablet.
- Conditions
- Healthy
- Being tested
- GLPG1972
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GLPG1972Drug
Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
| Study group | Role | What they receive |
|---|---|---|
| Treatment A | Experimental | GLPG1972 oral solution after overnight fast Receives: Drug: GLPG1972 |
| Treatment B | Experimental | GLPG1972 oral DC tablet after breakfast Receives: Drug: GLPG1972 |
| Treatment C | Experimental | GLPG1972 oral WG tablet after overnight fast Receives: Drug: GLPG1972 |
| Treatment D | Experimental | GLPG1972 oral WG tablet after breakfast Receives: Drug: GLPG1972 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of the maximum observed plasma concentration of GLPG1972 after single oral doses
Determine bioavailability of GLPG1972 by assessing PK parameters
Measured: on day 1 pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 and 48 hours post doses
Assessment of plasma concentration of GLPG1972 24hrs post-dose after single oral doses
Determine bioavailability of GLPG1972 by assessing PK parameters
Measured: At 24 hours post dose
Assessment of time to achieve the maximal plasma concentration of GLPG1972 after single oral doses
Determine bioavailability of GLPG1972 by assessing PK parameters
Measured: on day 1 pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 and 48 hours post doses
Assessment of the last quantifiable plasma concentration of GLPG1972 after single oral doses
Determine bioavailability of GLPG1972 by assessing PK parameters
Measured: on day 1 pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 and 48 hours post doses
Secondary outcomes (4)
the number of subjects with adverse events
To assess safety and tolerability of GLPG1972 given orally
Measured: at screening, pre-dose at date 1 and post-dose at 24 and 48 hours
the number of subjects with abnormal vital signs
To assess safety and tolerability of GLPG1972 given orally
Measured: at screening, pre-dose at date 1 and post-dose at 24 and 48 hours
the number of subjects with abnormal ECG
To assess safety and tolerability of GLPG1972 given orally
Measured: at screening, pre-dose at date 1 and post-dose at 24 and 48 hours
the number of subjects with abnormal laboratory assessments
To assess safety and tolerability of GLPG1972 given orally
Measured: at screening, pre-dose at date 1 and post-dose at 24 and 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2017
- Study start14 Apr 2017
- Primary completion6 Jun 2017
- Study completion6 Jun 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lakefront Biotherapeutics NV
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ann Fieuw, MD MSc, Study director, Lakefront Biotherapeutics NV
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03143725
- Sponsor's protocol ID
- GLPG1972-CL-105
- Status last verified
- Jun 2017
- First submitted
- 4 May 2017
- Last updated
- 20 Jun 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Open-label Study to Compare the Bioavailability of an Oral Wet Granulation Tablet of GLPG1972 Relative to an Oral Solution and to an Oral Direct Compression Tablet After Single-dose Intake in Healthy Subjects, and to Evaluate the Effect of Food on the Bioavailability of an Oral Wet Granulation Tablet.
- ClinicalTrials.gov ID
- NCT03143725
- Acronym / sponsor ID
- GLPG1972-CL-105
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Lakefront Biotherapeutics NVIndustry (pharma, biotech, devices)
- Study start
- 14 Apr 2017 (actual)
- Primary completion
- 6 Jun 2017 (actual)
- Study completion
- 6 Jun 2017 (actual)
- First posted
- 8 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a Phase I, randomized, open-label, cross-over study with 4 single-dose treatments of GLPG1972 to compare the bioavailability of the oral wet granulation (WG) tablet relative to an oral solution and to the oral direct compression (DC) tablet after single dose intake in healthy male subjects and to evaluate the effect of food on the bioavailability of the WG oral tablet.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Treatment A | Experimental | Drug: GLPG1972GLPG1972 oral solution after overnight fast |
| Treatment B | Experimental | Drug: GLPG1972GLPG1972 oral DC tablet after breakfast |
| Treatment C | Experimental | Drug: GLPG1972GLPG1972 oral WG tablet after overnight fast |
| Treatment D | Experimental | Drug: GLPG1972GLPG1972 oral WG tablet after breakfast |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Male between 18 and 50 years of age, inclusive,
- A body mass index (BMI) between 18-30 kg/m², inclusive, weight of at least 50 kg.
- Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and laboratory findings.
- Discontinuation of all medications except occasional paracetamol at least 2 weeks or 5 half-lives prior to the first study drug administration.
- Non-smokers and not using any nicotine-containing products.
Key exclusion criteria (18 listed)
- Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug
- Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or any history of hepatitis from any cause with the exception of hepatitis A.
- History of or a current immunosuppressive condition
- Symptoms of clinically significant illness in the 3 months before the initial study drug administration.
- History of malignancy within the past 5 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GLPG1972Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D) | Drug | Treatment A, Treatment B, Treatment C, Treatment D |
Primary outcome
Assessment of the maximum observed plasma concentration of GLPG1972 after single oral doses
Time frame: on day 1 pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 and 48 hours post doses
Determine bioavailability of GLPG1972 by assessing PK parameters
Assessment of plasma concentration of GLPG1972 24hrs post-dose after single oral doses
Time frame: At 24 hours post dose
Determine bioavailability of GLPG1972 by assessing PK parameters
Assessment of time to achieve the maximal plasma concentration of GLPG1972 after single oral doses
Time frame: on day 1 pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 and 48 hours post doses
Determine bioavailability of GLPG1972 by assessing PK parameters
Assessment of the last quantifiable plasma concentration of GLPG1972 after single oral doses
Time frame: on day 1 pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 and 48 hours post doses
Determine bioavailability of GLPG1972 by assessing PK parameters
4 secondary outcomes
the number of subjects with adverse events
Time frame: at screening, pre-dose at date 1 and post-dose at 24 and 48 hours
the number of subjects with abnormal vital signs
Time frame: at screening, pre-dose at date 1 and post-dose at 24 and 48 hours
the number of subjects with abnormal ECG
Time frame: at screening, pre-dose at date 1 and post-dose at 24 and 48 hours
the number of subjects with abnormal laboratory assessments
Time frame: at screening, pre-dose at date 1 and post-dose at 24 and 48 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jun 2017.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
Enrolling by invitationObservational study
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
Healthy Volunteer Samples
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
RecruitingPhase 1
A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body
Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ann Fieuw, MD MSc study director
Lakefront Biotherapeutics NV
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing GLPG1972 in people with Healthy, run by Lakefront Biotherapeutics NV at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of the maximum observed plasma concentration of GLPG1972 after single oral doses (time frame: on day 1 pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 and 48 hours post doses). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jun 2017.